These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19647224)

  • 1. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.
    Oravecz-Wilson KI; Philips ST; Yilmaz OH; Ames HM; Li L; Crawford BD; Gauvin AM; Lucas PC; Sitwala K; Downing JR; Morrison SJ; Ross TS
    Cancer Cell; 2009 Aug; 16(2):137-48. PubMed ID: 19647224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
    Philips ST; Hildenbrand ZL; Oravecz-Wilson KI; Foley SB; Mgbemena VE; Ross TS
    Oncogene; 2014 Nov; 33(46):5379-90. PubMed ID: 24240679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
    Buijs A; van Wijnen M; van den Blink D; van Gijn M; Klein SK
    Cancer Genet; 2013 Apr; 206(4):140-4. PubMed ID: 23751892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
    Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
    Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
    David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
    Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
    Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
    Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
    Magnusson MK; Meade KE; Nakamura R; Barrett J; Dunbar CE
    Blood; 2002 Aug; 100(3):1088-91. PubMed ID: 12130532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
    Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
    Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes.
    Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA
    Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
    Holtz MS; Bhatia R
    Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
    Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
    Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
    Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
    [No Abstract]   [Full Text] [Related]  

  • 18. TV6 and PDGFRB: a license to fuse.
    Lierman E; Cools J
    Haematologica; 2007 Feb; 92(2):145-7. PubMed ID: 17296561
    [No Abstract]   [Full Text] [Related]  

  • 19. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
    Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
    [No Abstract]   [Full Text] [Related]  

  • 20. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
    Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
    Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.